- Home
- PHAR vs PCRX Comparison
PHAR vs PCRX Comparison
Compare PHAR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PCRX
- Stock Information
- Founded
- PHAR 1988
- PCRX 2006
- Country
- PHAR Netherlands
- PCRX United States
- Employees
- PHAR N/A
- PCRX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- PCRX Health Care
- Exchange
- PHAR Nasdaq
- PCRX Nasdaq
- Market Cap
- PHAR 618.3M
- PCRX 1.2B
- IPO Year
- PHAR N/A
- PCRX 2011
- Fundamental
- Price
- PHAR $8.74
- PCRX $26.88
- Analyst Decision
- PHAR Strong Buy
- PCRX Buy
- Analyst Count
- PHAR 3
- PCRX 10
- Target Price
- PHAR $27.00
- PCRX $29.30
- AVG Volume (30 Days)
- PHAR 5.6K
- PCRX 892.8K
- Earning Date
- PHAR 03-13-2025
- PCRX 02-27-2025
- Dividend Yield
- PHAR N/A
- PCRX N/A
- EPS Growth
- PHAR N/A
- PCRX N/A
- EPS
- PHAR N/A
- PCRX N/A
- Revenue
- PHAR $285,745,000.00
- PCRX $694,957,000.00
- Revenue This Year
- PHAR $20.08
- PCRX $5.14
- Revenue Next Year
- PHAR $9.22
- PCRX $2.44
- P/E Ratio
- PHAR N/A
- PCRX N/A
- Revenue Growth
- PHAR 30.64
- PCRX 4.40
- 52 Week Low
- PHAR $6.65
- PCRX $11.16
- 52 Week High
- PHAR $13.20
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- PHAR 40.05
- PCRX 77.75
- Support Level
- PHAR $7.95
- PCRX $25.06
- Resistance Level
- PHAR $9.35
- PCRX $27.10
- Average True Range (ATR)
- PHAR 0.52
- PCRX 1.45
- MACD
- PHAR -0.16
- PCRX 0.28
- Stochastic Oscillator
- PHAR 22.76
- PCRX 86.23
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.